Related by context. All words. (Click for frequent words.) 72 corrected QT interval 70 thromboembolic events 70 QTc interval 70 QTc prolongation 69 QT interval 69 QTc intervals 68 QTcF 68 carotid IMT 67 ATACAND 67 lumbar spine BMD 66 β blockers 66 QT intervals 66 hypomagnesemia 66 creatinine clearance 66 RLAI 66 desvenlafaxine succinate 66 renal insufficiency 66 intima media thickness 65 insulin detemir 65 APTIVUS r 65 cerebrovascular events 65 lacosamide 65 atrioventricular block 65 BENICAR HCT 65 periprocedural 65 irbesartan 65 QRS duration 65 LVEF 65 transaminase levels 65 INVEGA ® 65 coadministration 65 symptomatic VTE 65 carotid intima media 65 virologic response 65 aminotransferases 65 beta blocker therapy 65 severe renal impairment 64 morphometric vertebral fractures 64 6MWD 64 colorectal adenoma 64 extrapyramidal symptoms 64 eptifibatide 64 macroalbuminuria 64 FAMPYRA 64 glycated hemoglobin levels 64 tipranavir r 64 prolonged QT interval 64 IIIa inhibitor 64 Pegylated Liposomal Doxorubicin 64 left ventricular dysfunction 64 QT QTc 64 atorvastatin #mg 64 hypocalcemia 64 GnRH agonist 64 Tasigna prolongs 64 definite stent thrombosis 64 radiographic progression 64 alteplase 64 ipsilateral stroke 64 urate lowering therapy 64 ziprasidone 63 activated partial thromboplastin 63 cardiac repolarization 63 moderate renal impairment 63 PEG IFN 63 divalproex sodium 63 tiotropium 63 ARCOXIA 63 intraobserver 63 epoetin beta 63 eplerenone 63 alanine aminotransferase 63 Bosentan 63 HOMA IR 63 mg BID 63 ULORIC 63 concomitant medications 63 antidiabetic medications 63 microalbuminuria 63 blood Phe 63 ventricular tachyarrhythmia 63 conjugated equine estrogen 63 atherothrombotic events 63 AST ALT 63 bosentan 63 FOLPI 63 serum testosterone 63 Pharmacokinetic 63 endometrial thickness 63 NIHSS score 63 renal dysfunction 63 echocardiographic 63 NATRECOR ® 63 nonfatal MI 63 zonisamide SR 63 achieved statistical significance 63 NPH insulin 63 thorough QT 63 teriflunomide 63 HbA1c levels 63 MADRS score 62 abatacept 62 DLTs 62 relapsed MM 62 hepatic enzymes 62 thromboembolic 62 MULTAQ 62 postintervention 62 GSK# [001] 62 noninferiority 62 adalimumab 62 ARIXTRA 62 tirofiban 62 tibolone 62 Ranolazine 62 timepoints 62 MMSE score 62 virologic failure 62 recurrent ischemia 62 platelet reactivity 62 aripiprazole 62 iloprost 62 dosage regimens 62 PEGINTRON TM 62 ABC/3TC 62 FASLODEX 62 oxycodone CR 62 tamsulosin 62 transaminases 62 Kaplan Meier analysis 62 anemia hemoglobin 62 lispro 62 serum phosphorous 62 HbA 1c 62 CIMZIA TM 62 neurologic symptoms 62 renal toxicity 62 quetiapine 62 virological response 62 LATUDA 62 somatostatin analog 62 serum aminotransferase levels 62 mg dose 62 mg kg dose 62 retinal thickness 62 genotypic resistance 62 adenoma recurrence 62 Betaferon ® 62 CrCl 62 thromboembolism 62 TEAEs 62 baseline HbA1c 62 renal impairment 62 metabolite concentrations 62 paroxysmal AF 62 paricalcitol 62 RoACTEMRA 62 elevated creatinine 62 placebo controlled clinical 62 intima media thickness IMT 62 recurrent VTE 62 VIIBRYD 62 D dimer 62 NIHSS 62 mycophenolate mofetil 62 NYHA functional class 62 postoperative complication 62 serum ALT 62 μg kg 62 ADAS Cog 62 azacitidine 62 serum phosphorus 62 QT prolongation 62 NNT = 62 MIRCERA 62 carotid stenosis 62 T2DM 62 β blocker 62 GAMMAGARD 62 HbA 1c levels 62 cardiac toxicity 62 PSA nadir 62 DAPT 62 sotalol 62 antiarrhythmic drug 62 serum creatinine levels 62 PRADAXA 61 plasma pharmacokinetics 61 neurologic progression 61 alanine aminotransferase ALT 61 icatibant 61 gadobutrol 61 #mg/day [001] 61 aspartate aminotransferase AST 61 FDG uptake 61 HBeAg seroconversion 61 PREZISTA r 61 LV ejection fraction 61 antiplatelet drugs 61 serum potassium 61 coronary stenosis 61 transaminase elevations 61 ARB telmisartan 61 serum cortisol 61 tapentadol ER 61 aspartate aminotransferase 61 resynchronization therapy 61 postoperative AF 61 rt PA 61 lumiracoxib 61 metabolic parameters 61 levodopa therapy 61 left ventricular systolic 61 mcg QD 61 mammographic density 61 Stent thrombosis 61 candesartan cilexetil 61 mL kg 61 PROMACTA 61 methylprednisolone 61 #mg BID [003] 61 coronary revascularization 61 moderate hepatic impairment 61 antidiabetic drug 61 liver histology 61 bolus dose 61 Primary endpoints 61 calculated creatinine clearance 61 NATRECOR R 61 Hb levels 61 reinfarction 61 PSADT 61 platelet inhibition 61 nadolol 61 unfractionated heparin 61 #mg/day [002] 61 myocardial ischemia 61 abacavir lamivudine 61 XIENCE V PROMUS Stent 61 glycosylated hemoglobin HbA1c 61 oral antidiabetic medication 61 tolvaptan 61 DOXIL 61 ranolazine 61 STRIDE PD 61 hypercalcemia 61 clinically meaningful improvement 61 RE LY 61 Cmax 61 gout flares 61 alpha blocker 61 inotropic 61 torsade de pointes 61 efalizumab 61 pioglitazone HCl 61 prospectively defined 61 thromboembolic complications 61 pulmonary artery pressure 61 valvulopathy 61 urine albumin 61 ACTOplus met 61 aldosterone antagonists 61 androgen deprivation 61 Subgroup analysis 61 ADAS cog 61 fluticasone salmeterol 61 serum estradiol 61 IFN beta 61 #mg dose [003] 61 ETDRS 61 events AEs 61 nondiabetic patients 61 COPAXONE R 61 hematologic toxicity 61 cardiac magnetic resonance 61 Non inferiority 61 ORENCIA ® 61 corticosteroid dose 61 tocilizumab 61 hepatotoxicity 61 rFVIIa 61 interobserver 61 mg QD 61 aPTT 60 BYSTOLIC 60 AVANDIA 60 multivariable analysis 60 VAPRISOL 60 thickness CIMT 60 Hypotension 60 RRMS patients 60 torsades de pointes 60 nonvertebral fracture 60 prespecified secondary 60 Secondary endpoints included 60 CK MB 60 cTnI 60 venous thromboembolic events 60 fluvastatin 60 hyperphenylalaninemia HPA due 60 otamixaban 60 ritonavir boosted 60 FDA defined valvulopathy 60 transdermal estradiol 60 pyridostigmine 60 dobutamine 60 SCr 60 PASI scores 60 pharmacokinetics PK 60 AUC0 60 periprocedural MI 60 thrombotic events 60 Pioglitazone 60 albumin excretion 60 sitaxsentan 60 infarct size 60 Patency 60 non valvular atrial 60 hematological parameters 60 serum PSA 60 posaconazole 60 ibandronate 60 unfractionated heparin UFH 60 proteinuria 60 TDF FTC 60 VELCADE melphalan 60 systemic embolism 60 fosamprenavir 60 atheroma volume 60 #mg dose [002] 60 REMINYL ® 60 MGd 60 angiotensin converting enzyme inhibitor 60 pCR 60 F FDG PET 60 EDSS score 60 serum sodium 60 pulmonary exacerbations 60 EXJADE 60 composite endpoint 60 #mg BID [001] 60 troponin T 60 dose titration 60 plasma uric acid 60 unstable angina pectoris 60 Toxicities 60 Left Ventricular Ejection Fraction 60 MACCE 60 pulmonary exacerbation 60 serum concentrations 60 abdominal circumference 60 adjunctive placebo 60 certolizumab 60 sub maximal 60 AGILECT R 60 P = .# 60 riociguat 60 APTIVUS 60 octreotide LAR 60 peginterferon alfa 2b 60 ventricular dysfunction 60 dopaminergic therapy 60 Hb A1C 60 -#.# ± [002] 60 hemoglobin Hb 60 salmeterol fluticasone 60 inhaled anticholinergics 60 nonvertebral fractures 60 statistical significance p 60 hsCRP 60 mCi 60 SSRI SNRI 60 nicardipine 60 cilostazol 60 μmol L 60 flutamide 60 HER2 expression 60 INFERGEN 60 HAQ DI 60 FOLFIRI 60 creatinine ratio 60 OGTT 60 octreotide 60 AZILECT R 60 Ejection Fraction 60 multivariate Cox 60 leukocyte count 60 severe neutropenia 60 ventricular tachyarrhythmias 60 Danazol 60 etanercept 60 lamotrigine 60 PrandiMet TM 60 oral anticoagulation 60 albumin excretion rate 60 aspirin clopidogrel 60 electrocardiographic 60 pg mL 60 ximelagatran 60 renal function 60 prolactin levels 60 angiographic restenosis 60 intratumoral 60 pentoxifylline 60 dosing cohort 60 serum potassium levels 60 plus medroxyprogesterone acetate 60 EDSS scores 60 univariate 60 vandetanib 60 tHcy 60 noninferior 60 NAbs 60 olanzapine 60 postprocedure 60 #mg QD [002] 60 pioglitazone 60 Torsades de Pointes 60 serum triglycerides 60 endometrial hyperplasia 60 COPAXONE ® 60 Thrombolysis 60 ictal 60 nonrandomized 60 L PPDS 60 antiarrhythmic drugs 60 lumbar spine bone 60 hypokalemia 59 Events MACE 59 serum HCV RNA 59 thromboprophylaxis 59 TAXUS Stent 59 mg TID 59 MERLIN TIMI 59 pramipexole 59 rosuvastatin #mg 59 fibrinolysis 59 #mg/m# [001] 59 ACTOplus met XR 59 bronchodilation 59 T2 lesions 59 TNF antagonist 59 CANCIDAS 59 serum urate 59 oral FTY# 59 postmenopausal osteoporotic women 59 foveal thickness 59 subclinical hypothyroidism 59 unresectable HCC 59 median PFS 59 thyroglobulin 59 dimeglumine 59 benazepril 59 preoperatively 59 IR prednisone 59 Lp PLA 2 59 CONCERTA ® 59 immunomodulatory therapy 59 ACTEMRA TM 59 ALT flares 59 surrogate endpoint 59 certolizumab pegol 59 TORISEL 59 EDARBI 59 diastolic BP 59 femoral neck BMD 59 p = .# [002] 59 dose proportionality 59 multicentre randomized 59 orthostatic hypotension 59 biochemical recurrence 59 mCi kg 59 pharmacodynamic parameters 59 myocardial perfusion 59 budesonide formoterol 59 hip BMD 59 laboratory abnormalities 59 ADCS CGIC 59 NIH CPSI 59 serum phosphate 59 MADIT CRT trial 59 sitagliptin 59 hepatic insufficiency 59 serum testosterone levels 59 pharmacokinetic PK 59 acetabular dysplasia 59 colesevelam HCl 59 epoetin alfa 59 dose cohort 59 spirometric 59 severe exacerbations 59 Hepatotoxicity 59 fasting glucose levels 59 albuminuria 59 ancrod 59 serum phosphate levels 59 mg BID dose 59 platelet inhibitor 59 macrovascular 59 acromegalic patients 59 leucopenia 59 hyperalgesia 59 serum IGF 59 Diovan HCT 59 nonsignificant 59 DES implantation 59 systolic BP 59 intermittent dosing 59 IFN α 59 lowest tertile 59 systolic hypertension 59 teriparatide 59 Hepatic Impairment 59 GP IIb IIIa inhibitors 59 systemic corticosteroids 59 renal artery stenosis 59 pegaptanib 59 LEXIVA 59 antihypertensive medications 59 cinacalcet 59 annualized relapse 59 sinus node dysfunction 59 plasma cortisol 59 ribavirin therapy 59 epoetin alpha 59 intravitreal injections 59 lactate dehydrogenase LDH 59 glomerular filtration rate 59 mesalamine granules 59 hyperkalemia 59 serum creatinine 59 recurrent venous thromboembolism 59 lymphocytosis 59 rCBF 59 PAOD 59 Apoptone 59 Randomized Evaluation 59 nephrotoxicity 59 budesonide pMDI 59 PreCISe study 59 RAPAFLO R 59 NSTE ACS 59 chemoradiotherapy 59 atypical antipsychotic medications 59 hypoglycemic events 59 oral diclofenac 59 abciximab 59 triiodothyronine 59 IELT 59 Hematologic 59 corticosteroid therapy 59 clinically meaningful improvements 59 comparator arm 59 hepatic fibrosis 59 Erythropoietic therapies may 59 dosing interval 59 androgen suppression 59 intravenous dosing 59 dopamine partial agonist 59 QRS width 59 Dasatinib 59 timepoint 59 pharmacokinetic PK profile 59 DMARD 59 glucocorticoid therapy 59 ischemic cardiomyopathy 59 ALT elevations 59 ug kg 59 hydroxymethyl coenzyme 59 inhaled iloprost 59 everolimus eluting stents 59 myocardial reperfusion 59 fasting triglycerides 59 HMG CoA reductase inhibitors 59 systemic corticosteroid 59 atazanavir ritonavir 59 Adalimumab 59 sinus tachycardia 59 mcg BID 59 LV hypertrophy 59 preoperative PSA 59 binary restenosis 59 tumor histology 59 anticoagulation therapy 59 angiographically 59 overt nephropathy 59 depressive symptomatology 59 mTSS 59 poor metabolizers 59 ventricular arrhythmia 59 treatment emergent adverse 59 posttreatment 59 EFFEXOR XR 59 solifenacin 59 elevated ALT 59 LV dysfunction 59 evaluable subjects 59 primary aldosteronism 59 dosing intervals 59 doxorubicin docetaxel 59 Torisel 59 olmesartan 59 haematologic 59 Severity MSCS score 59 intact parathyroid hormone 59 hypoperfusion 59 ALA PDT 59 echocardiographic parameters 59 oxcarbazepine 59 cerebral perfusion 59 Lamictal XR 59 extensive metabolizers 59 carotid endarterectomy CEA 59 attain statistical significance 59 warfarin therapy 59 tranylcypromine 59 events TEAEs 59 demonstrated clinically meaningful 59 bronchial hyperresponsiveness 59 hemodynamically significant 59 symptom exacerbation 59 viral kinetics 59 risperidone Risperdal 59 urinary calcium 59 urinary albumin 59 #mg dose [001] 59 GnRH agonists 59 carotid artery stenosis 59 neuropsychiatric symptoms 58 bisoprolol 58 mg/m2 dose 58 glatiramer acetate 58 Subgroup analyzes 58 SUSTENNA TM 58 ECG abnormalities 58 tanespimycin 58 intravascular ultrasonography 58 AGILECT ® 58 thienopyridine 58 CYPHER R Sirolimus eluting 58 fasting plasma glucose 58 Secondary endpoints 58 elevated transaminases 58 % Confidence Interval 58 Y BOCS 58 adrenocorticotropic hormone 58 MADIT II 58 SIMPADICO 58 CIMZIA ™ 58 serum lipid 58 mg/# h 58 DULERA 58 HPA axis suppression 58 peak VO2 58 inhaled budesonide 58 intraocular inflammation 58 COPD exacerbations 58 Elitek 58 Febrile neutropenia 58 LVSD 58 strontium ranelate 58 dipyridamole plus 58 opioid analgesia 58 #mg QD [001] 58 cytopenias 58 intracerebral hemorrhage 58 galiximab 58 Castration Resistant Prostate Cancer 58 angiographic outcomes 58 gliclazide 58 dimensional echocardiography 58 hyperintense lesions 58 eszopiclone 58 dronedarone 58 myopathy rhabdomyolysis 58 HIV HCV coinfected 58 cisplatin vinorelbine 58 CVD mortality 58 EBRT 58 hemoglobin A1c levels 58 antipsychotic efficacy 58 LANTUS R 58 ventricular repolarization 58 hemorrhagic complications 58 atherosclerotic renal artery stenosis 58 boosted protease inhibitor 58 pharmacodynamic 58 lanreotide 58 VADT 58 microvessel density 58 vasomotor symptoms 58 interferon gamma 1b 58 TYGACIL 58 HSCT 58 primidone 58 PRADAXA #mg 58 EURIDIS 58 bezafibrate 58 stable angina 58 aminotransferase levels 58 upper gastrointestinal bleeding 58 Bone Mineral Density 58 interobserver reliability 58 maximal doses 58 pericardial effusion 58 brivaracetam 58 REYATAZ ritonavir 58 dose regimens 58 Pharmacokinetic parameters 58 pretest probability 58 bendamustine 58 logistic regression model 58 gadolinium enhanced 58 estimated glomerular filtration 58 fasting insulin 58 candesartan 58 Index CDAI 58 formoterol fumarate 58 metformin sulfonylurea 58 clopidogrel Plavix 58 QT Prolongation 58 Peg IFN 58 sulfasalazine 58 clinically meaningful 58 PegIntron 58 tacrolimus ointment 58 CCyR 58 events SAEs 58 denileukin diftitox 58 glomerular filtration 58 ± SD 58 NYHA Class II 58 ABCB1 58 6R BH4 58 YMRS 58 KAPIDEX 58 biologic DMARD 58 Postoperative 58 fondaparinux 58 paraprotein 58 elotuzumab 58 dual endothelin receptor antagonist 58 paroxetine sertraline 58 piperacillin tazobactam 58 serum lipid levels 58 Cypher Stent 58 pomalidomide 58 cranial irradiation 58 levetiracetam 58 serum PTH 58 fallopian tube cancers 58 fosbretabulin 58 extubation 58 Mylotarg 58 liver transaminases 58 pulmonary capillary wedge 58 serum uric acid 58 Teriflunomide 58 AZOR 58 hyperbilirubinemia 58 apnea hypopnea index 58 WOMAC pain 58 Lantus R 58 hemoglobin A1c HbA1c 58 Renal dysfunction 58 pg ml 58 levosimendan 58 hsCRP levels 58 peginterferon alfa 58 neostigmine 58 active comparator 58 serum sodium levels 58 serum BDNF 58 glycemia 58 adrenal insufficiency 58 advanced adenomas 58 pulmonary arterial 58 gadolinium enhancing lesions 58 central corneal thickness 58 sustained ventricular tachycardia 58 pharmacodynamics PD 58 pharmacodynamic PD 58 prednisone prednisolone 58 lipid lowering agents 58 methotrexate monotherapy 58 hypogonadal men 58 vertebral fracture 58 Tolvaptan 58 insulin glargine 58 serum calcium levels 58 Peginterferon Alfa 2a 58 PEGylated interferon beta 1a 58 perioperative complications 58 dyspnoea 58 hematologic parameters 58 Postoperative complications 58 Solid Tumors criteria 58 primary generalized tonic 58 PCWP 58 rotigotine 58 prostate cancer CaP 58 NMIBC 58 BENICAR 58 #mg doses [002] 58 aortic regurgitation 58 oral rivaroxaban 58 Focalin XR 58 placebo controlled trials 58 dose dexamethasone 58 selenium supplementation 58 amisulpride 58 thrombus aspiration 58 ACE inhibitor ramipril 58 hemodynamic parameters 58 PANSS scores 58 recombinant tissue plasminogen 58 secondary efficacy endpoint 58 BARACLUDE r 58 LHRH agonists 58 chemoradiation therapy 58 chlorambucil 58 clomipramine 58 leflunomide 58 dalteparin 58 perioperatively 58 Secondary endpoints include 58 progression TTP 58 QD dosing 58 histopathologic 58 liposomal amphotericin B 58 lymphadenectomy 58 reflux symptoms 58 statistically significant p = 58 lactic acidosis 58 prospectively randomized 58 darbepoetin alfa 58 Visual Analogue Scale VAS 58 oxyhemoglobin 58 headache nasopharyngitis 58 QRS interval 58 ICD shocks 58 COPD exacerbation 58 coronary stenoses 58 x ULN 58 MBq 58 cystoscopic 58 PRISTIQ 58 eculizumab therapy 58 symptomatic hyponatremia 58 â ‰ ¥ 58 mg/m2/day 58 Relapsing Remitting Multiple Sclerosis 58 severe renal insufficiency 58 ejection fractions 58 RISPERDAL ® 58 serum bilirubin 58 antibody titer 58 MEVACOR 58 mucosal healing 58 ventricular dyssynchrony 58 triamcinolone 58 canakinumab 58 pheochromocytoma 58 fraction LVEF 58 Monotherapy 58 bolus injection 58 ertapenem 58 TOPAMAX 58 gastric pH 58 venlafaxine XR 58 ARIMIDEX 58 8mg/kg 58 mapatumumab 58 advanced adenoma 58 Lantus ® 58 mL/min/#.# m 2 58 nonfatal myocardial infarction 58 chest radiography 58 sirolimus eluting stents 58 intraocular pressure IOP 58 caspofungin 58 ≥ 58 Topiramate 58 mg d 58 plasma renin activity 58 carotid plaque 58 rFSH 57 Protelos 57 chest radiographs 57 abdominal adiposity 57 placebo p = 57 thrombotic complications 57 placebo controlled studies 57 virological failure 57 Brief Psychiatric 57 microg 57 mL/min/#.# m2 57 hepatic impairment 57 hyperglycaemia 57 deep venous thromboses 57 vildagliptin 57 sUA 57 mcg kg 57 endoscopic gastric ulcers 57 Candesartan 57 oral antidiabetes 57 CD4 + cell 57 recurrent glioblastoma multiforme 57 arterial thromboembolic events 57 decitabine 57 Known hypersensitivity 57 neutrophil counts 57 postoperative mortality 57 treatment emergent AEs 57 dyssynchrony 57 pharmacodynamic effects 57 lymphopenia 57 antidiabetic drugs 57 detemir 57 mitoxantrone 57 Montgomery Asberg Depression 57 Crohn Disease Activity 57 biphasic insulin aspart 57 Ki# 57 antihypertensive therapy 57 Perforomist Inhalation Solution 57 estimated GFR 57 #.#g/day 57 Natalizumab 57 mcg dose 57 TRIZIVIR 57 thyrotoxicosis 57 secondary efficacy endpoints 57 RE LY ® 57 LEXIVA r 57 5-FU/LV 57 complete cytogenetic response 57 dose limiting toxicities 57 lipid lowering therapy 57 antibiotic prophylaxis 57 INVEGA 57 neuroleptic 57 urinary N telopeptide 57 Multiple Ascending Dose 57 CC genotype 57 ONGLYZA 57 mycophenolate mofetil MMF 57 nonmetastatic prostate cancer 57 CI -#.# 57 glycosylated hemoglobin levels 57 cardiac troponin 57 ezetimibe simvastatin 57 goserelin 57 postoperatively 57 melphalan prednisone 57 CorVue ™ 57 elevated troponin 57 PSA kinetics 57 pegylated interferon alfa 2b 57 ropivacaine 57 thyrotropin 57 Ambulatory Blood Pressure 57 nelfinavir 57 left ventricular hypertrophy 57 pharmacokinetic parameters 57 ablative therapy 57 CLA supplementation 57 serum magnesium 57 myocardial viability 57 Randomized clinical trials 57 mometasone furoate 57 BoNTA 57 #mmHg [001] 57 ZOLINZA 57 ARCALYST ® 57 ml kg 57 DAS# scores 57 quetiapine XR 57 endometrial carcinoma 57 dose Iluvien 57 multivariable Cox 57 HRCT 57 postoperative chemotherapy 57 glucose tolerance test 57 uncorrected visual acuity 57 safinamide 57 adrenalectomy 57 eosinophilia 57 divalproex 57 CIMZIA R 57 Bezielle 57 Telithromycin 57 receiving INTRON 57 clevidipine 57 valsartan 57 hemodynamic variables 57 plus MTX 57 Paliperidone 57 AUCs